CHICAGO, July 27, 2021 /PRNewswire/ — According to the new market research report “Clinical Trial Imaging Market by Software & Services(Operational Imaging, Read Analysis), Modality(CT, MRI, X-ray, PET, Ultrasound, ECHO), Therapeutic Areas(Infectious, Oncology, CNS, CVS), End user(Pharma, biotechnology, CRO) – Global Forecast to 2026″, published by MarketsandMarkets™, the global market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 7.6%.
Browse in-depth TOC on “Clinical Trial Imaging Market”
198 – Tables
38 – Figures
206 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30446624
The Increase in R&D spending, growth in pharmaceutical and biotechnology industries and increasing number of CROs are among the other factors. Emerging economies such as China, India and Japan are providing lucrative opportunities for the players operating in the market.
The services segment accounted for the largest share of the market, by product and service segment, in 2020
Based on product and service, the clinical trial imaging market is segmented into services and software. The services segment accounted for the largest share of the market in 2020. Factors such as the and growth in pharmaceutical and biotechnology industries and the increase in R&D spending are contributing for the growth of this market.
Positron emission tomography segment to register the highest growth rate during the forecast…
